Overview

Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Breast Cancer

Status:
Recruiting

Trial end date:
2024-11-20

Target enrollment:

Participant gender:

Summary

Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

Carboplatin
Docetaxel
Trastuzumab